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palifermin on the incidence of mucositis in children
following AHSCT has never been studied. In this retrospec-
tive study, we compared the incidence of mucositis and
supportive care required in childrenwho received palifermin
vs. controls (no palifermin) during non-TBI AHSCT. Mucositis
was graded as per WHO criteria. The continuous variables
were summarized by the mean and standard deviation; the
categorical variables were summarized by percentage. The
palifermin vs. control group were compared by two-sided t-
test for continuous measurements and by Chi-square test for
categorical measurements. From 2005-2011, 58 patients
received myeloablative AHSCT, of which n¼25 were in the
palifermin group and n¼33 were in the control group.
Demographic characteristics are presented in Table.
Comparing palifermin vs. the control group: the average time
for neutrophil engraftment was 12.163.21 days vs. 11.5
1.68 (P¼.127), the incidence of grade I and III-IVmucositis
was 80% vs. 90.9%, and 20% (P¼ .02) vs. 42.4% (P¼.07), the
number of days with fever were 4.923.49 vs. 7.094.86
(P¼.063), the number of days patients received PCA were
8.808.39 vs. 8.308.54 (P¼.826), and the number of days
patients were on TPN were 13.5211.32 vs. 11.559.63
(P¼.484), respectively. The incidence of blood stream and
Clostridium difﬁcile infection was 36% vs. 27.3% (P¼.4) and
24% vs. 18.2% (P¼.5), respectively. The average length of
hospital stay 31.447.42 vs. 28.6110.38 (P¼.252) was not
statistically different between the palifermin and control
groups. In summary, we were unable to demonstrate that
there was a statistical difference with incidence of mucositis
and other supportive care needs or a decrease in hospital
stay in the palifermin group. In children receiving AHSCT,
palifermin should only be used in the setting of a large
prospective study.Variable Control group
(No Palifermin,
n¼33) Mean (SD)
Palifermin group
(n¼25)Mean (SD)
P-value
Age 6.85 (5.49) 7.96 (6.19) .473
Gender:
Male 20 (60.6%) 14 (56%) .724
Female 13 (39.4%) 11 (44%)
Weight 30.62 (27.08) 35.02 (25.95) .535
BSA 0.98 (0.55) 1.05 (0.51) .580
Brain Tumor 15 (45.5%) 3 (12%) .024
Solid Tumor 11 (33.3%) 14 (56%)
Lymphoma 7 (21.2%) 8 (32%)
Disease Status .671
CR/PR 29 (87.9%) 21 (84.0%)
SD/PD 4 (16%) 4 (12.1%)
Prior Radiation: .120
Yes 3 (9.1%) 6 (24%)
No 30 (90.9%) 19 (76%)
HSV serostatus: .330
Positive 25 (75.8%) 16 (64%)
Negative 8 (24.2%) 9 (36%)
Creatinine clearance 118.1 (42.55) 134.8 (49.31) .176TRANSPLANT PHARMACY ORAL
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Background: The use of ﬁlgrastimwith or without plerixafor
has been shown to be an effective modality for the mobili-
zation of peripheral blood stem cells. However, questions
remain as to the CD34+ count that would best predict for
efﬁcient collection. We developed a ﬁlgrastim-based mobi-
lization algorithm with a predetermined decision point for
the inclusion of plerixafor and a CD34+ count of 20 cells/uL as
the trigger for collection. The purpose of our evaluation was
to determine the efﬁcacy of this algorithm, as well as the
impact on plerixafor use, in patients undergoing mobiliza-
tion with ﬁlgrastim prior to autologous hematopoietic stem
cell transplant (HSCT).
Methods: Patients received ﬁlgrastim 10 mcg/kg SC once
daily for 4 days. If the day 5 CD34+ count was > 20/ul,
apheresis was started and ﬁlgrastim was continued until the
collection goal was met. If the day 5 CD34+ count was <10,
plerixafor was started, and if the day 5 CD34+ count was 10-
20, ﬁlgrastim was continued for 1 day with plerixafor added
if the day 6 CD34+ count remained <20/uL. Mobilization
efforts were stopped if the blood CD34+ count remained <
10. The CD34+ cell collection goal was 4 x 106 cells/kg, with
a minimum requirement of 2 x 106 to proceed to HSCT.
Results: To date, 21 patients (18 multiple myeloma and 3
other) have been treated. Fifteen of 18 myeloma patients
received prior lenalidomide therapy. Eleven of the 21
patients were successfully mobilized using ﬁlgrastim alone.
Nine patients who had inadequate CD34+ mobilization with
ﬁlgrastim alone responded to the addition of plerixafor.
Patients requiring plerixafor received an average of 1.56
doses. One patient with non-Hodgkin's lymphoma had no
response to ﬁlgrastim and therefore mobilization attempts
were halted. Seventeen of the 21 patients have successfully
proceeded to transplant, with 3 of the remaining 4 expected
to be admitted for HSCT within the next month. Patients
collected in an average of 1.7 apheresis sessions and collected
an average of 5.15 x 106 CD34+ cells/kg.
Conclusion: We demonstrate here a successful and cost-
effective algorithm-based approach to mobilization,
including a predetermined strategy to include plerixafor for
poormobilizers. By using a decision point for the inclusion or
exclusion of plerixafor, we avoided use of the agent in
patients unlikely to need it for successful collection.122
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Background: Chemotherapy plus GCSF has been an effective
modality for the mobilization of peripheral blood stem cells.
However, the optimal drug, dose, and schedule have not
